New TRU NIAGEN® Stick Packs Target New Audiences and Consumer Needs
November 20 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU
NIAGEN stick packs, offering a new delivery method of its
revolutionary nicotinamide riboside ingredient to promote cellular
energy and repair.
The stick packs, which each provide 300mg nicotinamide riboside
mixed with fiber source inulin (chicory root extract), will offer
consumers single-serving packets that easily mix into both cold and
hot beverages, including smoothies and coffee. The product is
particularly convenient for those who are on-the-go, athletes who
consume sports drinks with a number of ingredients, and those who
can’t swallow capsules. The product is also vegetarian and
caffeine-free.
“We are pleased to introduce this new way to ingest Tru Niagen,”
says ChromaDex CEO Rob Fried. “It could be particularly helpful to
those who prefer sports or nutrition beverages to capsules.”
The new product is now available on Amazon.com, Upgrade Labs,
select Pressed Juicery locations in Los Angeles, as well as Make
Out and New Deli restaurants from James Beard Award winner, Matthew
Kenney.
“This new Tru Niagen product is the perfect add-on to a juice,
smoothie or just on its own,” says Kenney. “We are excited to offer
them to our health-conscious community.”
“Upgrade Labs is the first-ever biohacking human upgrade
facility utilizing data-driven technology, focused on improving
one’s health, quality of life, and longevity,” said Martin Tobias,
CEO Upgrade Labs. “Part of our unique inside-out approach
begins with ways we can improve cellular health. With the latest in
NAD technology from Tru Niagen, Upgrade Labs’ clients are able to
enhance cellular energy production and promote overall cellular
health with ease.”
For additional information on the science supporting TRU NIAGEN
visit www.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is an
integrated, global nutraceutical company devoted to improving the
way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof. ChromaDex
provided research materials and a portion of the grant funding as a
collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor
Relations949-344-3782briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024